Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ATR protein kinase inhibitor VE 822, 10 mg  

ATR protein kinase inhibitor VE 822, 10 mg

5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine

VE 822 is a selective ATR inhibitor

More details

PKI-VE822-010

Availability: within 3 days

162,50 €

Background: VE 822 is a selective ATR protein kinase inhibitor (IC50 values 0.019 µM, 2.6 µM, and 18.1 µM for ATR, ATM, and DNA-PK, respectively) with in vitro and in vivo activity that decreases maintenance of cell-cycle checkpoints and homologous recombination in irradiated cancer cells, and increases persistent DNA damage. VE822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.

Chemical formula: C24H25N5O3S
Molecular weight: 463.55 g/mol
Purity: 99 %
Appearance: Yellow solid
Solubility: Soluble in 0.1N HCl(aq) and DMSO
CAS Number: 1232416-25-9

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

E. Fokas et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012 Dec 6;3:e441.